

EASD 2026 Preview – Clinical and AI / ML



LucidQuest Intelligence
Accelerate your success



EASD 2026 Preview – Table of Contents

• <u>New Trends in Diabetes Treatment Strategy At EASD'26</u>	<u>3-6</u>
• <u>Key Sessions To Watch</u>	<u>7</u>
• <u>Industry-sponsored Sessions & Focus Areas At EASD 2026</u>	<u>8-16</u>
• <u>Competitive Landscape At a Glance at EASD 2026</u>	<u>9-10</u>
• <u>Key Industry-sponsored Sessions At EASD 2026</u>	<u>11-15</u>
• <u>New Entrants</u>	<u>16</u>
• <u>AI/ML Trends & Strategic Watchpoints At EASD 2026</u>	<u>17-19</u>
• <u>AI / Digital Health Angle At EASD 2026</u>	<u>18-19</u>
• <u>What We're Watching For Post-congress</u>	<u>20</u>
• <u>Get In Touch With LucidQuest</u>	<u>21</u>

EASD 2026 – New Trends in Diabetes Treatment Strategy (1/4)



- **Will incretin-based care move further from glucose and weight management toward broader cardiometabolic outcomes?**

- Novo Nordisk, Lilly, AstraZeneca and Boehringer Ingelheim will frame obesity and T2D management around broader metabolic health, including cardiovascular, renal and liver considerations. Sessions on semaglutide, GLP-1/glucagon biology, holistic cardiometabolic care and multidimensional metabolic health will test how far treatment discussions will extend beyond HbA1c and body weight



- **How will the next wave of amylin-based therapies reshape the obesity and T2D conversation?**

- Novo Nordisk will place amylin biology, CagriSema, cagrilintide and zenagamtide at the centre of several sessions, while the scientific programme will include clinical data for zenagamtide and CagriSema alongside other emerging approaches. The competitive question will be how these approaches could expand treatment options beyond established incretin-based strategies



EASD 2026 – New Trends in Diabetes Treatment Strategy (2/4)



• **Will earlier intervention become a more explicit strategy across diabetes and obesity**

- The conference will feature early-stage T1D detection and care through multiple Sanofi sessions, while Novo Nordisk, Merck, Menarini and Lilly will address earlier intervention across obesity, diabetes prevention and metabolic disease. The programme will therefore examine earlier identification, earlier treatment and longer-term disease management across different points of the diabetes continuum



• **How will diabetes technology evolve from monitoring toward integrated decision-making?**

- Abbott, Roche, Dexcom/Sanofi, SIBIONICS and mylife Diabetes Care will focus on CGM, dual sensing, predictive monitoring, AI, automated insulin delivery and integrated sensing/therapy. The tension will be whether technology remains primarily a monitoring tool or becomes more deeply integrated into treatment optimisation and clinical decision pathways



- **Can treatment strategies increasingly address diabetes-related complications beyond glycaemic control?**

- Boehringer Ingelheim, Bayer-supported Sciarc, Menarini and PeerVoice/EFIM Academy will focus on cardiovascular, renal and metabolic risk, while Novo Nordisk and AstraZeneca will also connect metabolic treatment with kidney, heart and liver outcomes. The sessions will reinforce a broader treatment framework in which diabetes management extends beyond glucose control



- **How will diabetes care increasingly intersect with liver disease and MASH?**

- Madrigal will focus specifically on liver-directed treatment with resmetirom in people with diabetes and MASH, while AstraZeneca and Novo Nordisk will incorporate liver health into broader metabolic disease discussions. EASD 2026 will therefore provide multiple perspectives on how MASH and metabolic disease may be addressed within diabetes care



- **Will new treatment formats and delivery approaches change practical diabetes management?**

- Lilly will focus on once-weekly insulin efsitora alfa, while Novo Nordisk will address injectable and oral semaglutide and Sanofi will examine practical early-stage T1D pathways. Technology-focused sessions will additionally address automated insulin delivery, patch pumps and sensing, bringing formulation, frequency and delivery technology into the broader treatment discussion



Key Sessions To Watch

Date	Session Title (short)	Type	Author / Institution	Why Watch
29 Sep 2026	Efficacy and safety of retatrutide in T2D - TRANSCEND-T2D-1	Oral	Harpreet S. Bajaj / Seattle, USA	The presentation will provide clinical results for retatrutide, a GLP-1/GIP/glucagon receptor agonist, in T2D treated with diet and exercise alone
29 Sep 2026	Major adverse cardiovascular events: semaglutide 2.0 mg vs tirzepatide	LBA	Gang Fang / Tianjin, China	The analysis will examine cardiovascular outcomes among people with T2D escalating to semaglutide 2.0 mg versus switching to tirzepatide
29 Sep 2026	CagriSema and body composition - REIMAGINE 1	LBA	Jøran Hjelmæsæth / Tonsberg, Norway	The presentation will provide CagriSema data on body composition in participants with early T2D
30 Sep 2026	Zenagamtide (amycretin): Phase 2 results in T2D	Oral	Pablo Mora / Plano, USA	The presentation will provide Phase 2 clinical results for the GLP-1/amylin receptor agonist zenagamtide
30 Sep 2026	CagriSema and CGM — REIMAGINE 2	LBA	Julia Mader / Hangzhou, China	The presentation will examine the effect of CagriSema on continuous glucose monitoring in inadequately controlled T2D
01 Oct 2026	Sustained glycaemic improvements with Omnipod 5 - RADIANT extension	LBA	Pieter Gillard / Leuven, Belgium	The presentation will provide extended-use data for the Omnipod 5 automated insulin delivery system
01 Oct 2026	Sensor continuity and glycaemic outcomes with MiniMed 780G and Instinct CGM	LBA	Jennifer McVean / Jacksonville, USA	The presentation will provide real-world data from 11,520 users on sensor continuity and glycaemic outcomes

Industry-Sponsored Sessions & Focus Areas – EASD 2026





EASD 2026– Competitive Landscape at a Glance (1/2)

Name	Sessions	Companies / Assets	Why It Matters
Incretin, Obesity & Cardiometabolic Care	Multiple	Novo Nordisk, Lilly, Amgen, Regeneron, AstraZeneca, Boehringer Ingelheim, Menarini	The presentations will examine obesity and T2D through GLP-1, glucagon, semaglutide and broader metabolic-health approaches
Amylin & Next-Generation Metabolic Therapies	Multiple	Novo Nordisk; CagriSema; cagrilintide; zenagamtide	Multiple Novo sessions plus scientific presentations will put amylin biology and next-generation combination approaches under discussion
Early T1D Detection & Disease Modification	Multiple	Sanofi; teplizumab; T1D autoantibody testing	Sanofi will address detection, pathway development, C-peptide preservation and teplizumab treatment in early-stage autoimmune T1D
CGM, Sensing & Digital Diabetes Care	Multiple	Abbott, Roche, Dexcom/Sanofi, SIBIONICS, mylife Diabetes Care	Sessions will move from glucose monitoring toward predictive sensing, dual sensing, AI and integration with therapy
Cardiorenal Risk Reduction	Multiple	Boehringer Ingelheim, Bayer/Sciarc, Menarini, PeerVoice/EFIM	Cardiovascular and renal risk will be repeatedly positioned alongside glycaemic management
MASH & Metabolic Liver Disease	Multiple	Madrigal/resmetirom, AstraZeneca, Novo Nordisk	Diabetes specialists will be exposed to liver-directed treatment alongside broader metabolic approaches



EASD 2026– Competitive Landscape at a Glance (2/2)

Name	Sessions	Companies / Assets	Why It Matters
Insulin & Treatment Delivery	Multiple	Lilly/efsitora alfa, Sanofi-Dexcom, Novo Nordisk, mylife Diabetes Care	The programme will address once-weekly insulin, basal insulin optimisation, CGM-guided treatment and automated insulin delivery
Emerging Adjacent Approaches	Multiple	Sobi/apoC-III inhibition, Merck/metformin, embecta	Additional sessions will address severe hypertriglyceridemia, diabetes prevention and injection technique



Key Industry-Sponsored Sessions at EASD 2026 (1/5)



- **Novo Nordisk:**

- Focus Areas: Semaglutide, Amylin & CagriSema, Zenagamtide, Cardiometabolic Care
- Sessions will cover injectable and oral semaglutide, optimisation of glucose and weight management, early intervention in obesity, holistic cardiometabolic care, amylin biology, CagriSema, cagrilintide and zenagamtide. The programme will span established semaglutide-based care and the emerging amylin-focused pipeline across obesity and T2D



- **Eli Lilly:**

- Focus Areas: Cardiometabolic Disease, Oral Therapies, Insulin Efsitora Alfa
- Sessions will cover obesity and T2D, emerging oral therapies, new mechanisms in cardiometabolic care and the evolution of basal insulin with once-weekly insulin efsitora alfa. The programme will address both emerging cardiometabolic treatment approaches and practical evolution of insulin therapy



Key Industry-Sponsored Sessions at EASD 2026 (2/5)



- **Sanofi:**

- Focus Areas: Early-Stage T1D, Teplizumab, T1D Autoantibody Testing
- Presentations will cover scalable T1D autoantibody testing, early detection pathways, adult dysglycaemia diagnosis, C-peptide preservation and real-world experience with teplizumab. The programme will focus on building an early-stage T1D pathway from detection through treatment



- **Sanofi-Dexcom:**

- Focus Areas: Basal Insulin, CGM, AI-Enabled Diabetes Management
- The focus will be on basal insulin therapy, CGM-guided basal insulin optimisation in T2D and the use of AI in therapeutic management. The programme will connect insulin treatment with technology-enabled optimisation and AI-supported decision-making



Key Industry-Sponsored Sessions at EASD 2026 (3/5)



• **Abbott / Abbott Diabetes Care:**

- Focus Areas: CGM, Dual Sensing, T1D & T2D
- Dual sensing, DKA prevention, iCGM, personalised HbA1c optimisation, CGM use in basal-insulin-treated T2D and the FreeDM2 study will be discussed. The programme will position sensing technology across both T1D and T2D while expanding beyond conventional glucose monitoring



• **AstraZeneca:**

- Focus Areas: GLP-1 & Glucagon Physiology, Obesity, CKD & MASH
- The session will cover metabolic disease pathophysiology, glucose and weight regulation, CKD and MASH. The programme will connect metabolic biology with kidney and liver disease across the broader cardiometabolic spectrum



Key Industry-Sponsored Sessions at EASD 2026 (4/5)



- **Boehringer Ingelheim:**

- Focus Areas: SGLT2 Inhibition, Cardiorenal Protection, Metabolic Health
- The experts will discuss comprehensive T2D care, guideline considerations and cardiovascular and renal benefits of SGLT2 inhibitors, alongside obesity as a systemic disease and multidimensional metabolic health. The programme will connect established cardiorenal management with a broader biology-driven approach to metabolic disease



- **Amgen:**

- Focus Areas: Obesity Biology, Long-Term Obesity Management, Patient-Centred Care
- The presentations will cover obesity as a chronic disease, its underlying biology and the challenges of long-term management. The programme will focus on how obesity management can be structured around longer-term and patient-centred care



Key Industry-Sponsored Sessions at EASD 2026 (5/5)



• **Regeneron:**

- Focus Areas: Obesity, Weight Loss & Broader Health Outcomes
- The session will address obesity, weight-loss expectations and the question of whether weight loss alone is sufficient. The programme will use an expert-panel format to explore broader considerations in obesity management



• **Madrigal Pharmaceuticals:**

- Focus Areas: MASH in Diabetes, Resmetirom, Liver-Directed Treatment
- The session will cover identifying people with MASH in diabetes care, treatment with resmetirom and liver disease beyond glycaemic and weight effects. The programme will focus on integrating liver-directed MASH management into diabetes clinics



New Entrants

Asset / Company	2026 Presence
Zenagamtide (amycretin)	Zenagamtide (amycretin), a novel unimolecular GLP-1 and amylin receptor agonist: Phase 2 results in type 2 diabetes
Olatorepatide	Efficacy and safety of olatorepatide, a novel dual-biased GLP-1/GIP receptor agonist in Chinese adults with overweight or obesity: a randomised, double-blind, placebo-controlled, phase 3 study
HRS-4729	Safety, tolerability, pharmacokinetics, and pharmacodynamics of HRS-4729, a novel GLP-1/GIP/glucagon triple-receptor agonist: a randomised, double-blind, placebo-controlled Phase 1 study
SHR-3167	Efficacy and safety of once-weekly insulin SHR-3167 vs daily insulin degludec in type 2 diabetes participants previously treated with basal insulin with or without oral antidiabetic drugs
CT-996	Safety and pharmacodynamics of CT-996, an oral small molecule, cAMP signal-biased GLP-1 receptor agonist, over 4 weeks in adults with overweight/obesity and type 2 diabetes
BGM0504	Efficacy and safety of BGM0504 in Chinese patients with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled Phase 3 trial
MTX-101	Phase 1A/B study evaluating the safety, pharmacokinetics, and pharmacodynamics of MTX-101 in healthy adults and type 1 diabetes patients
XTL6001	XTL6001: a novel triple MasR/GCGR/GLP-1R agonist for weight loss and obesity-related complications



AI/ML Trends & Strategic Watchpoints at EASD 2026





AI / Digital Health Angle at EASD 2026 (1/2)

- **AI and digital-health activity at EASD 2026 will span clinical decision support, glucose management, screening, diabetes education and remote care, rather than being limited to technology-focused sessions. The programme will feature AI/ML applications in diabetic retinopathy screening, CGM optimisation, glycaemic-risk prediction, diabetes classification, treatment decision-making and complication-risk assessment**
- **AI will increasingly be positioned alongside diabetes technologies such as CGM, automated insulin delivery and digital therapeutics. Dedicated sessions will examine how AI-derived insights, CGM data, algorithms, digital twins and connected technologies could support more personalised diabetes management and improve treatment decisions**
- **Key sessions include:**
 - AI in diabetes 2026: from agentic systems to responsible deployment, covering responsible AI in diabetes care and the use of agentic AI and digital twins in diabetes management
 - Tackling vascular challenges related to diabetes by using AI: Navigating uncharted waters, including AI for diabetic retinopathy screening, CGM optimisation, heart-failure diagnostics and guideline use



AI / Digital Health Angle at EASD 2026 (2/2)

- An update on AI and machine learning in type 1 diabetes and complications, spanning AI-based CGM phenotyping, digital twins, smartphone-based carbohydrate estimation, ML-based treatment decisions, multimodal AI for retinopathy and LLM-based risk prediction
- Role of digitalisation in type 2 diabetes management, featuring CGM-derived machine-learning classification and wearable-based ML for non-invasive diabetes detection
- **Sessions suggest AI and digital tools are increasingly being used to improve:**
 - Risk prediction and screening through AI/ML models and AI-supported retinal assessment
 - Glycaemic management through CGM-linked AI, algorithms and automated insulin delivery
 - Personalised decision-making through digital twins, ML-derived phenotyping and treatment-decision models
 - Patient self-management and education through smartphone applications and AI-enabled digital-health platforms
 - Remote diabetes care through telemedicine and connected diabetes technologies



What We're Watching for Post-EASD 2026

- Whether emerging therapies can improve glycaemic control while addressing weight, cardiovascular and renal outcomes, particularly as incretin-based and combination strategies evolve
- Whether new evidence reshapes treatment approaches across type 1 and type 2 diabetes, including insulin, GLP-1 receptor agonists, glucose-lowering and combination therapies across patient profiles
- Whether advances in diabetes technology translate into broader clinical benefits, with focus on CGM, automated insulin delivery, closed-loop systems, connected devices and real-world performance
- Whether earlier detection and risk stratification can alter the trajectory of diabetes and its complications, spanning screening, prediction, biomarkers, vascular complications and personalised management
- Whether diabetes management moves further toward personalised care, incorporating clinical characteristics, treatment response, lifestyle, nutrition, comorbidities and patient-reported outcomes
- Whether integrated care gains greater importance beyond glucose management, particularly across cardiovascular and kidney disease, obesity, liver disease, complications and other comorbidities
- Whether implementation and health-system factors become increasingly important for routine adoption, including real-world effectiveness, healthcare utilisation, cost, education, access and adoption of therapies and technologies



Strategic Insights and Strategy Development is our focus

COMPETITIVE STRATEGY
AND INTELLIGENCE



DIGITAL HEALTH, ARTIFICIAL
INTELLIGENCE AND IoE



GENE & CELL THERAPY



VACCINES & INFECTIOUS
DISEASES



INVESTMENT INSIGHTS

e: INFO@LQVENTURES.COM

w: WWW.LQVENTURES.COM